1. Folklore
H E L E N A B I O I N F O R M A T I C S CROSSROADS 2026 From а whole-genome to review, in minutes Vladimir Mitev, Founder and CEORESEARCH USE ONLY
Read the slide text
2. The problem
THE PROBLEM Sequencing gets cheaper. Interpretation stays slow and costly 01 / THE PROBLEM 001 Too slow Geneticists piece together evidence across separate tools. Too expensive Large annual licences are hard to justify at low case volumes. Interpretation is the bottleneck Small labs need speed and a price that fits their case volume. READING THE GENOME
3. The solution
THE SOLUTION Fast, affordable genomic analysis 02 / THE SOLUTION 002 WGS VCF classification and prioritisation WGS PROCESSING PAY PER CASE 5–10 min LOW COST Less manual work. No annual subscription. Automation brings the evidence together for the geneticist. Franklin WGS processing: 2–3 hours. READING THE GENOME
4. What we have built
WHAT WE HAVE BUILT Automated variant analysis. Evidence in one place 03 / WORKING PRODUCT / RESEARCH USE ONLY 003 Built with CellGenetics For laboratories with their own genetics specialists. READING THE GENOME
5. Clinical evidence
CLINICAL EVIDENCE Clinically tested 04 / CLINICAL EVIDENCE 004 Retrospective evaluation with CellGenetics CLINICAL CASES COHORTS 197 4 Methodology published in Frontiers in Genetics “A methodological framework for real-world performance studies of clinical variant classification platforms at early organizational stages” Mitev (2026), doi.org/10.3389/fgene.2026.1925492 READING THE GENOME
Read the methodology in Frontiers in Genetics6. Early adoption
EARLY ADOPTION Working product. First external users 04 / EARLY ADOPTION 004 11 registered accounts Registration cohort: 15–30 September 2026 2 accounts completed an analysis Own data, including free evaluations. Signed distribution with ELTA90M A route to genetics laboratories in Bulgaria. READING THE GENOME
7. The team
THE TEAM Built by an engineer. Guided by geneticists 05 / THE TEAM 005 Vladimir Mitev, Founder and CEO 20+ years in software. 10 years in management. Product developer. Academician Prof. Draga Toncheva Chair, Scientific and Clinical Advisory Board. CellGenetics Founding clinical partner. Development with practising geneticists. READING THE GENOME
8. What comes next
H E L E N A B I O I N F O R M A T I C S CROSSROADS 2026 Next: first paying laboratories, then regional growth Capital for sales and distribution 5 laboratory introductions and 1 regional partner Planned service for labs without geneticists Sequencing, analysis and genetic consultation vladimir@helena.bio folklore.helena.bio